Company information lookup

Go

View full list of companies

VIRALYTICS LIMITED (VLA)

On this page you will find:

Company snapshot
Delayed share price
Company announcements
Price history chart
Exchange Traded Options 		ASX-Listed Emblem Company details
Closing prices
Dividends
Warrants & Structured Products
ASX CFDs

Delayed share price

Prices are delayed by 20 minutes unless stated otherwise in the Conditions. Retrieving any price indicates your acceptance of the Conditions.

Code Last % Chg Bid Offer Open High Low Vol
VLA 0.295 3.51% 0.285 0.295 0.295 0.295 0.290 23,390

ASX Find a broker tool

Helps you find an ASX broker based on your needs and where you live.

VIRALYTICS LIMITED details

Please note: ASX relies on third parties to provide the information contained in the company details table, and therefore is unable to assume any responsibility for the accuracy or timeliness of the information.

Issuer Code VLA
Securities
Official Listing Date 15 October, 1986
GICS Industry Group Pharmaceuticals, Biotechnology & Life Sciences
Exempt Foreign? No
Internet Address http://www.viralytics.com/
Registered Office Address McCullough Robertson, Level 11, 66 Eagle Street, BRISBANE, QLD, AUSTRALIA, 4001
Share Registry LINK MARKET SERVICES LIMITED
LEVEL 15, 324 QUEEN STREET, BRISBANE, QLD, AUSTRALIA, 4000
Share Registry Telephone 1300 554 474
Directors / Senior Management
Mr Paul Hopper (Chairman)
Dr Malcolm McColl (CEO)
Dr Phillip Altman (Non Exec. Director)
Mr Peter Molloy (Non Exec. Director)
Dr Leonard Post (Non Exec. Director)
Company Secretary Ms Sarah Prince

VIRALYTICS LIMITED announcements

How are company announcements published on www.asx.com.au?

Date Price
sens.		 Headline Pages PDF
16/05/2013   Progress of CAVATAK phase II trial to be presented at ASCO 2 PDF
01/05/2013   Shareholder Newsletter 5 PDF
26/04/2013   Chairman's role 1 PDF
16/04/2013 asterix Appendix 4C - quarterly 5 PDF
09/04/2013 asterix Positive results for Viralytics CAVATAK phase 1 IV Study 2 PDF
03/04/2013   Shareholder and Investor Presentation 21 PDF
25/03/2013   CAVATAK featured in presentation at US Oncology Conference 2 PDF
22/03/2013 asterix Viralytics comment on results from Amgen Phase 3 trial 1 PDF
21/03/2013 asterix Acceleration of Patient Recruitment in Phase 2 Study 1 PDF
07/03/2013   Change of facsimile number 1 PDF

> search for past company announcements

Viewing Company Announcements:
Users of Adobe Acrobat Reader version 6.0.0 may have difficulty accessing PDF announcements. Symptoms include slow downloads, blank documents, and small white boxes appearing in the PDF. We recommend you download the latest version of the free Adobe Acrobat Reader. To check which version you have, open Adobe Acrobat Reader, click on 'Help', then click 'About Adobe Reader 6.0'.

Closing prices

Closing prices are displayed for the last 5 days on which the security traded on ASX within the last 6 months.

Date Last % Change High Low Vol *
22 May 2013 0.285 0% 0.290 0.285 131,021
21 May 2013 0.285 -1.72% 0.285 0.285 20,900
20 May 2013 0.290 1.75% 0.295 0.290 85,214
17 May 2013 0.285 0% 0.300 0.285 72,300
16 May 2013 0.285 -1.72% 0.300 0.285 77,666

* Volume of shares shown represents only those shares traded on ASX.

VIRALYTICS LIMITED price history chart

* More charting options are available.

Dividends

How are dividends released on www.asx.com.au?

No dividends have been found for the security VLA. This is likely to be because a dividend has not been announced to the ASX by this company during the specified timeframe or a dividend has been announced but is not yet available on this website.

Exchange Traded Options

No Exchange Traded Options are available over the security VLA

Warrants & Structured Products

No warrants & Structured Products are available over the security VLA

ASX CFDs

No Contracts For Differences are available over the security VLA